Chemotherapy for Small-Cell Lung Cancer: Comparing 12 vs 6 Courses
Author Information
Author(s): Professor N.M. Bleehen, Mr P.M. Fayers, Dr D.J. Girling, Mr R.J. Stephens
Primary Institution: Medical Research Council
Hypothesis
Does extending chemotherapy from six to twelve courses improve survival in small-cell lung cancer patients?
Conclusion
Continuing chemotherapy beyond six courses does not provide a significant survival advantage and may worsen quality of life.
Supporting Evidence
- 85% of patients had a response to initial chemotherapy.
- Median survival was 39 weeks with 31% alive at 1 year.
- Maintenance chemotherapy did not show a significant survival advantage.
- Quality of life was better for patients who did not receive maintenance chemotherapy.
Takeaway
Doctors wanted to see if giving more chemotherapy would help people with lung cancer live longer, but it didn't really help and made them feel worse.
Methodology
Patients were randomly assigned to receive either six or twelve courses of chemotherapy after an initial treatment phase.
Potential Biases
Potential bias in patient selection and response assessment.
Limitations
The study may not apply to all patients, especially those with different responses to initial treatment.
Participant Demographics
Patients aged 75 years or less with untreated small-cell lung cancer.
Statistical Information
P-Value
0.27
Confidence Interval
37-43
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website